investor-relations/MBPL Seed Bridge CCD.tex

\documentclass[DIV13,a4paper]{scrartcl}

\usepackage[utf8]{inputenc}
\usepackage[english]{babel}


\usepackage[sfdefault, light]{FiraSans}
\usepackage[T1]{fontenc}
\usepackage{textcomp}

\usepackage{geometry}
\geometry{margin=0.57in,tmargin=0.27in}
\usepackage{listings}
\usepackage{tabularx}
\usepackage{booktabs}
\usepackage{grid-system}

\usepackage{xcolor}
\definecolor{linkcolor}{rgb}{0, 0, 0.93}

\usepackage{tikz}

\usepackage[
hidelinks,
colorlinks=true,
urlcolor=linkcolor
]{hyperref}

\newcommand{\roundpic}[4][]{
	\tikz\node [circle, minimum width = #2,
	path picture = {
		\node [#1] at (path picture bounding box.center) {
			\includegraphics[width=#3]{#4}};
	}] {};}

\setlength{\parindent}{0cm}
\lstset{language=[LaTeX]tex,xleftmargin=2em}

\begin{document}
	\section*{}
	
	\begin{row}[cellsep=0.25cm]{16}{4}
		\begin{cell}{10}
		\vspace{-6ex}
		{\large 
			{\bfseries Mandala Bioworks Private Limited}}\\
		\small Investor Note - Pre-Seed Round November 2021	
		\end{cell}
		\begin{cell}{2}
			\roundpic[xshift=0cm,yshift=0cm]{1.8cm}{2.5cm}{"images/sid.jpg"}		
		\end{cell}
		\begin{cell}{2}
			\roundpic[xshift=0cm,yshift=0cm]{1.8cm}{2.5cm}{"images/aishwarya.jpg"}		
		\end{cell}
		\begin{cell}{2}
			\roundpic[xshift=0cm,yshift=0cm]{1.8cm}{2.5cm}{"images/rupam.jpg"}		
		\end{cell}
	\end{row}
	\begin{row}[cellsep=0.25cm]{12}{3}
		
	\end{row}
	
	\vspace{-8ex}
	\section*{Introduction}
	\begin{row}{16}{2}
		\begin{cell}{7}
			Mandala Bioworks Private Limited (MBPL) was incorporated on 18\textsuperscript{th} August 2020. \\
			
			The MBPL team came together to play a part in the exciting and growing worldwide effort to make biosciences and biotechnology more consumer accessible and consumer friendly. 
			
			In our first year of existence we have successfully developed breakthrough technologies towards the same via the Govt. of India's BIG grant, and validated our technology at lab and pilot scale.\\
		\end{cell}
		\begin{cell}{9}
			We believe human diagnostics in particular will be substantially less invasive while being cheaper and faster in the near future. They may even be increasingly possible to do at home, on a more periodic if not daily basis. \\
			
			COVID-19 has made palpable the consumer demand for these products and services and created a wave of interest that is drawing the best minds, scientists, engineers and investors who will be engaged in solving these problems and bringing them to market. MBPL seeks to be a dominant market leader in the coming Consumer Biotechnology revolution.
			
		\end{cell}
	\end{row}
	\vspace{3ex}
	\textcolor{gray}{\rule{47em}{1pt}} \\
	\begin{row}{16}{2}
		\begin{cell}{8}
			\section*{The Holy Grail of Consumer Biotech}	
			In order to be consumer friendly, whether in the lab or at home, this paradigm shift requires that conventional tests are reimagined and redesigned to work with the smallest and least invasive sample possible - fingerprick blood, if not ideally saliva etc.\\
			
			So far only a few such tests have reached commercial viability. Primarily this is on account of the fact that, while a small sample of saliva or fingerprick blood can be easily extracted, the subsequent testing is much more complicated. \\
		\end{cell}
		\begin{cell}{8}	
			\section*{Why is this so hard?}
			The compounds that are being detected in a few mircoliters of saliva or blood are often many magnitudes below the detection capabilities of current systems. Our current tests have been designed to expect much larger volumes in order to make these reactions work and interface with the sensors that we have been using successfully for decades to detect and quantify these often invisible reactions.\\
			
			When you change the scale, the rules change too. We need to redesign core systems to make these tests work.
		\end{cell}
	\end{row}

	\begin{row}{16}{2}
		\begin{cell}{10}
			\section*{The Mandala Advantage}
			MBPL has developed a detection system that breaks through this barrier using bioluminescence - the light emitting chemistry of nature - most popularly depicted in fireflies.\\
			
			Our system can work at volumes that make saliva/fingerprick testing etc viable, detect extremely faint light signals many magnitudes below the state of the art flourescence based detection systems on the market. And it can be easily adapted for multiple targets, so that a range of tests and methods that were restricted to research settings may now be commercialised on top of these technologies. \\ 
			
			Our bioluminescent probe system is also cost effective. 
			
			The base cost per test is \textbf{less than two US dollars.} 
			
			The base cost of the detection system is \textbf{less than four hundred US dollars.}
		\end{cell}
		\begin{cell}{6}
			\vspace{5.5ex}
			\roundpic[xshift=0cm,yshift=0cm]{5.8cm}{5.5cm}{"images/proto.jpg"}		
		\end{cell}
	\end{row}
	
	\medskip
	\section*{Business Model (Seed to Series A)}
	\begin{row}{15}{3}
		\begin{cell}{5}
			\textbf{Business Activities \& Costs}
			\begin{list}{$\bullet$}{\leftmargin=1em \itemindent=0em \itemsep=0em}	
				\item Our core business activity is the development, refinement and patenting of our core platform modules and technologies
				\item We are also developing a few practical use cases of tests that are considered particularly challenging for demonstration, benchmarking and marketing purposes
				\item Our immediate focus is to find teams working on human testing parameters for lifestyle diseases, as we believe there is a strong market demand from a younger health conscious generation for the same
				\item Our immediate cost outlay is towards team building, equipment, machinery, consumables and legal expenses
			\end{list}
		\end{cell}	
		\begin{cell}{5}
			\textbf{Value Proposition \& Revenues}
			\begin{list}{$\bullet$}{\leftmargin=1em \itemindent=0em \itemsep=0em}
				\item Our modules \& technologies help research teams and biotech entrepreneurs rapidly iterate, validate and commercialise accessible tests that work with small sample volumes (saliva, fingerprick blood etc) for which there is a growing consumer demand
				\item MBPL is an enabler (like stripe or razorpay for ecommerce) and does not currently intend to put its own tests and products directly in the market
				\item MBPL at this juncture, believes this would result in better RoI and earlier revenues and growth
			\end{list}
		\end{cell}
		\begin{cell}{5}
			\textbf{Markets \& Customers}
			\begin{list}{$\bullet$}{\leftmargin=1em \itemindent=0em \itemsep=0em}
				\item We license and sell modules, assays, know how and software to research teams, biotech startups and diagnostic test \& device manufacturers
				\item MBPL believes this enables a core, nimble technology company to go to market in multiple geographies with multiple customer developed products, and establish its reputation and reliability
				\item MBPL believes such an approach would mainly mitigate the regulatory and market costs \& risks involved, at least until the circumstances change and force MBPL to reconsider a more direct to customer business model
			\end{list}
		\end{cell}	
	\end{row}

	\medskip	
	\section*{Business Goals \& Requirements}
	
	\begin{row}{12}{2}
		\begin{cell}{6}
			\textbf{Immediate Goals \& Objectives}
			\begin{list}{$\bullet$}{\leftmargin=1em \itemindent=0em \itemsep=0em}
				\item Product Development \& Refinement
				\item Example Test Development for product demos
				\item Team Building
				\item Lab Infrastructure building
				\item Patents \& IP applications
			\end{list}	
		\end{cell}
		\begin{cell}{6}
			\textbf{Pre Seed Funding Offer}
			\begin{list}{$\bullet$}{\leftmargin=1em \itemindent=0em \itemsep=0em}
				\item Pre Seed Raise Total of 3Cr INR
				\item Structured as Compulsory Convertible Debentures at annualised 10\%
				\item 20\% discount for CCD holders on valuation at Seed stage (principal + interest)
				\item Target valuation for Seed stage is 15M USD
				\item Further details available in offer document on request (Floor, cap etc)
			\end{list}
		\end{cell}
	\end{row}
	
	\section*{Contact Us}
	For confidentiality reasons, this brief investor prospectus does not delve into the details and nuances of the product/technology, our approach to the problem, and our core business strategy and philosophies. Please get in touch with us if you would like to know more, or let us know if you would like to visit our office to meet the team and review our product, setup and capabilities before investing. \\

	\medskip
	\begin{row}{30}{3}
		\begin{cell}{8}
			\textbf{Sidharth Sudarshan}
			
			Staff, Strategy \& Product
			
			\texttt{sid@mandala.bio}
			
			\texttt{+91-9538850530}
		\end{cell}
		\begin{cell}{11}
			\textbf{Aishwarya Nair}
			
			Research, Projects \& Performance
			
			\texttt{anair@mandala.bio}
			
			\texttt{+91-8669297541}
		\end{cell}
		\begin{cell}{11}
			\textbf{Rupam Mazumdar}
			
			Innovation, Growth \& Automation 
			
			\texttt{rupam@mandala.bio}
			
			\texttt{+91-9886782174}
		\end{cell}
	\end{row}

	\medskip
	\vspace{1ex}
	\textbf{Mandala Bioworks Private Limited} - 3036, 8th Main, HAL 2nd Stage, Bangalore, India 560008
\end{document}